Yehuda Handelsman, MD-Chair
Medical Director
Metabolic Institute of America
Tarzana, CA
Stuart Shankland, MD
Belding H. Scribner Endowed Chair of Medicine
Head, Division of Nephrology
University of Washington School of Medicine
Seattle, WA
Dace Trence, MD
Assistant Professor of Medicine
Director, Diabetes Care Center
University of Washington School of Medicine
Seattle, WA
Virginia Valentine, NP
Clinical Nurse Specialist, Diabetes
CEO, Diabetes Network
Albuquerque, NM
|
The burden of type 2 diabetes mellitus (T2DM), in terms of morbidity,
mortality, complications, and economic burden, is high and is predicted
to rise even further. According to estimates from the US Centers
for Disease Control and Prevention (CDC), between 7% and 8% of
the population has T2DM, but this is projected to increase to 30% of
the population within the next 30 years. The greatest increases are
estimated to occur in African Americans and Hispanics, and in women
(regardless of race or ethnicity). In addition, although diabetes screening
has long been recommended for individuals beginning at around
50 years of age, this is no longer the case. Given the changing-and
already altered-demographics of T2DM, clinicians should be monitoring
for the disease in all patients over 30 years of age.
Both microvascular (retinopathy, neuropathy, and nephropathy) and
macrovascular (cardiovascular diseases) complications are consequences
of less-than-optimal control of several important clinical
parameters in patients with existing T2DM. Therefore, it is crucial that
health care providers focus not only on good control of serum glucose
but also on blood pressure and lipids as well.
This supplement is designed to provide needed updates in the identifi
cation and treatment of patients with T2DM, in order to reduce
complications and the societal/medical burden of this disease.
|
Dr Handelsman has received grant/research support from Daiichi
Sankyo, GlaxoSmithKline, Novartis, Novo Nordisk Inc., Takeda, sanofi -
aventis, Tolerx, and XOMA. He has also received honoraria for being
a consultant and/or serving on the speakers bureau for AstraZeneca,
Bristol-Myers Squibb Company, Daiichi Sankyo, Gilead, Genentech,
GlaxoSmithKline, Merck, Novartis, Takeda, Thetys, Tolerx, and XOMA. Dr Handelsman is on the editorial advisory board of Clinical
Endocrinology News. Dr Trence has been a shareholder of Medtronic and sanofi -aventis. Dr Shankland has no relevant financial relationships with any commercial
interests. Ms Valentine has received honoraria for being a consultant and/or
serving on the speakers bureau and/or being a member of an advisory
board for Amylin, Abbott Diabetes Care, Asante Solutions Inc.,
Boehringer Ingelheim, Calibra, Cequr, Dexcom, Intuity Medical, Eli Lilly
and Company, Medtronic, F. Hoffman-La Roche Ltd., Pamlab, Takeda,
and Tandem Pumps. CHSE committee members have no relevant fi nancial relationships
with any commercial interests: Carolyn Burns, MD; Dedra DeBerry, MA;
Joyce Dunagan, MA, MSLS; Linda H. Freeman, DNS, RN; Terri Gipson,
MSL; Ruth Greenberg, PhD; Lucy Juett, MS; Irene Litvan, MD; Loretta
Maldaner; Mike Mansfi eld, DMD; Ashlee Melendez, RN, BSN; Lisa J.
Pfi tzer, MD; Robert Sexton, MD; Uldis Streips, PhD; Kathy M. Vincent, MD;
Lori Wagner, MD; Stephen Wheeler, MD; and Sharon Whitmer, EdD.
CHSE offi ce staff members Jim Creg, Kim Moore, and Joyce Korfhage
have no relevant relationships with any commercial interests. Shirley Jones, Sylvia Reitman, and Michelle Rizzo with the Global
Academy for Medical Education and medical writer Joanne Still have
no relevant relationships with any commercial interests. CME Reviewer: Ann Moore, MSN, RNC, FAANP, Professor of Nursing,
Vanderbilt University School of Nursing, Nashville, TN, has no relevant
relationships with any commercial interests. RESOLUTION OF CONFLICT OF INTEREST
The CHSE has implemented a process to resolve conflict of interest for each CME activity. In order to help ensure content objectivity, independence and fair balance and to ensure that the content is aligned with the interest of the public, CHSE has resolved the conflict by external content review. Unapproved/Off-Label Use Disclosure
CHSE requires CME faculty to disclose to the participants:
1. When products or procedures being discussed are off-label, unlabeled, experimental, and or investigational (not US Food and Drug Administration [FDA] approved); and
2.Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that are outside of FDA-approved labeling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. None of the authors discusses off-label uses of any FDA-approved drugs. |
